Rasim Şahin

Rasim Şahin

Auto-generated profile, based on publicly available information

Rasim Şahin

Saglik Bilimleri Universitesi Kayseri Tip Fakultesi

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025
Verified
Preprint
Open access
OÇOlgu Erkin Çınar
Olgu Erkin Çınar
AKAzade Kanat
Azade Kanat
KEKerim Erer
Kerim Erer
RŞRasim Şahin
Rasim Şahin
EEEsma Eryılmaz Eren
Esma Eryılmaz Eren
EYEsra Yıldızhan
Esra Yıldızhan
Background: Venetoclax-based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real-world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low-dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥2 IAEs occurred, with an incidence of 1 per 121 patient-days. Multivariate analysis identified prolonged neutropenia (days, OR=1.037, p=0.005) and interacting concomitant medications (OR=9.99, p<0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs. Conclusion: IAEs remain a substantial risk in venetoclax-treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.

26 January 2026
Verified
Preprint
Open access
KEKeri̇m Erer
Keri̇m Erer
RŞRasim Şahin
Rasim Şahin
YKYavuz Katırcılar
Yavuz Katırcılar
FTFatoş Tekelioğlu
Fatoş Tekelioğlu
SKSerdal Korkmaz
Serdal Korkmaz

22 December 2025 in Cancer Reports
Verified
Journal Article
Open access
OÇOlgu Erkin Çınar
Olgu Erkin Çınar
AKAzade Kanat
Azade Kanat
KEKerim Erer
Kerim Erer
RŞRasim Şahin
Rasim Şahin
EEEsma Eryilmaz-Eren
Esma Eryilmaz-Eren
EYEsra Yıldızhan
Esra Yıldızhan
Background: Venetoclax‐based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real‐world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low‐dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥ 2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥ 2 IAEs occurred, with an incidence of 1 per 121 patient‐days. Multivariate analysis identified prolonged neutropenia (days, OR = 1.037, p = 0.005) and interacting concomitant medications (OR = 9.99, p < 0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs. Conclusion: IAEs remain a substantial risk in venetoclax‐treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.